ADIL Adial Pharmaceuticals Inc

1.62
+0.02  (+1%)
Previous Close 1.6
Open 1.61
Price To Book 1.65
Market Cap 16,592,767
Shares 10,242,449
Volume 46,651
Short Ratio
Av. Daily Volume 45,795
Stock charts supplied by TradingView

NewsSee all news

  1. Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    CHARLOTTESVILLE, VA / ACCESSWIRE / October 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of treatments for

  2. Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided

  3. Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today

  4. Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    Application for pediatric investigation plan waiver validated by European Medicines Agency CHARLOTTESVILLE, VA / ACCESSWIRE / September 5, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial due to commence December 2019 with data due in 2021. Data from second Phase 3 trial for U.S. required endpoint due 2023.
AD04
Alcohol use disorder

Latest News

  1. Adial Pharmaceuticals Announces Mark Howard Peikin, Esq. as Chief Strategy Officer and VP of Corporate Communications as Adial Advances Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    CHARLOTTESVILLE, VA / ACCESSWIRE / October 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of treatments for

  2. Adial Provides Update on Clinical Activities; Filing to Commence Phase 3 Trial on Track for Q3 2019

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today provided

  3. Adial Pharmaceuticals Announces Successful Product Retesting of AD04 for Phase 3 Clinical Trial

    CHARLOTTESVILLE, VA / ACCESSWIRE / September 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today

  4. Adial Pharmaceuticals Completes Key Regulatory Milestone Prior to Commencing European Phase 3 Clinical Trial of AD04 for the Treatment of Alcohol Use Disorder

    Application for pediatric investigation plan waiver validated by European Medicines Agency CHARLOTTESVILLE, VA / ACCESSWIRE / September 5, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage